Growth in children receiving contemporary disease specific therapy for Crohn's disease

Salma Malik, Avril Mason, Andisheh Bakhshi, David Young, Jonathan Bishop, Victoria Garrick, Paraic McGrogan, Richard K Russell, S Faisal Ahmed

Research output: Contribution to journalArticle

Abstract

IntroductionIt is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD).AimTo assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD.What is already known on this topic ▶ Growth retardation may occur in children with Crohn's disease (CD). ▶ Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids.What this study adds ▶ Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. ▶ There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease.Methods The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9–15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4–19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF.Results At T0, mean height SD score (HtSDS) was −0.5 (−3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (−2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was −0.6 (−4.8 to 7.8), −0.6 (−2.9 to 2.2), −0.7 (−3.6 to 2.5) and −0.5 (−3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was −1.4 (−7.4 to 7.4), −0.6 (−7.5 to 6.1), −0.1 (−6.6 to 7.6) and 0.6 (−4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02).Conclusion Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases.
Original languageEnglish
Pages (from-to)698-703
Number of pages6
JournalArchives of Disease in Childhood
Volume97
Issue number8
Publication statusPublished - 1 Jun 2012
Externally publishedYes

Fingerprint

Crohn Disease
Growth
Therapeutics
Prednisolone
Chronic Disease
Weights and Measures
Azathioprine
Methotrexate
Glucocorticoids

Cite this

Malik, S., Mason, A., Bakhshi, A., Young, D., Bishop, J., Garrick, V., ... Ahmed, S. F. (2012). Growth in children receiving contemporary disease specific therapy for Crohn's disease. Archives of Disease in Childhood, 97(8), 698-703.
Malik, Salma ; Mason, Avril ; Bakhshi, Andisheh ; Young, David ; Bishop, Jonathan ; Garrick, Victoria ; McGrogan, Paraic ; Russell, Richard K ; Ahmed, S Faisal. / Growth in children receiving contemporary disease specific therapy for Crohn's disease. In: Archives of Disease in Childhood. 2012 ; Vol. 97, No. 8. pp. 698-703.
@article{bcd6b447615c4e6e8475b6619979017b,
title = "Growth in children receiving contemporary disease specific therapy for Crohn's disease",
abstract = "IntroductionIt is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD).AimTo assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD.What is already known on this topic ▶ Growth retardation may occur in children with Crohn's disease (CD). ▶ Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids.What this study adds ▶ Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. ▶ There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease.Methods The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9–15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4–19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF.Results At T0, mean height SD score (HtSDS) was −0.5 (−3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (−2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was −0.6 (−4.8 to 7.8), −0.6 (−2.9 to 2.2), −0.7 (−3.6 to 2.5) and −0.5 (−3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was −1.4 (−7.4 to 7.4), −0.6 (−7.5 to 6.1), −0.1 (−6.6 to 7.6) and 0.6 (−4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02).Conclusion Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases.",
author = "Salma Malik and Avril Mason and Andisheh Bakhshi and David Young and Jonathan Bishop and Victoria Garrick and Paraic McGrogan and Russell, {Richard K} and Ahmed, {S Faisal}",
year = "2012",
month = "6",
day = "1",
language = "English",
volume = "97",
pages = "698--703",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "8",

}

Malik, S, Mason, A, Bakhshi, A, Young, D, Bishop, J, Garrick, V, McGrogan, P, Russell, RK & Ahmed, SF 2012, 'Growth in children receiving contemporary disease specific therapy for Crohn's disease' Archives of Disease in Childhood, vol. 97, no. 8, pp. 698-703.

Growth in children receiving contemporary disease specific therapy for Crohn's disease. / Malik, Salma; Mason, Avril; Bakhshi, Andisheh; Young, David; Bishop, Jonathan; Garrick, Victoria; McGrogan, Paraic; Russell, Richard K; Ahmed, S Faisal.

In: Archives of Disease in Childhood, Vol. 97, No. 8, 01.06.2012, p. 698-703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Growth in children receiving contemporary disease specific therapy for Crohn's disease

AU - Malik, Salma

AU - Mason, Avril

AU - Bakhshi, Andisheh

AU - Young, David

AU - Bishop, Jonathan

AU - Garrick, Victoria

AU - McGrogan, Paraic

AU - Russell, Richard K

AU - Ahmed, S Faisal

PY - 2012/6/1

Y1 - 2012/6/1

N2 - IntroductionIt is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD).AimTo assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD.What is already known on this topic ▶ Growth retardation may occur in children with Crohn's disease (CD). ▶ Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids.What this study adds ▶ Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. ▶ There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease.Methods The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9–15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4–19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF.Results At T0, mean height SD score (HtSDS) was −0.5 (−3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (−2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was −0.6 (−4.8 to 7.8), −0.6 (−2.9 to 2.2), −0.7 (−3.6 to 2.5) and −0.5 (−3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was −1.4 (−7.4 to 7.4), −0.6 (−7.5 to 6.1), −0.1 (−6.6 to 7.6) and 0.6 (−4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02).Conclusion Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases.

AB - IntroductionIt is unclear whether recent therapeutic advances have improved the growth of children with Crohn's disease (CD).AimTo assess the frequency of short stature and poor growth and their relationship to disease course and therapy in children with CD.What is already known on this topic ▶ Growth retardation may occur in children with Crohn's disease (CD). ▶ Current therapy for CD in the UK is less likely than previously to involve the use of long-term glucocorticoids.What this study adds ▶ Despite advances in therapy, short stature and slow growth continue to be encountered in children with CD. ▶ There is a need for simple and consistent definitions of growth that can identify poor growth in children with chronic disease.Methods The anthropometric and treatment details of 116 children (68 male) with a mean (range) age at diagnosis of 10.8 years (4.9–15.5) and a mean age at maximum follow-up (MF) of 15.4 years (9.4–19.3) were studied retrospectively at diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at MF.Results At T0, mean height SD score (HtSDS) was −0.5 (−3.3 to 2.6) compared to a mid-parental HtSDS of 0.2 (−2.0 to 01.4) (p=0.002). At T1, T2, T3 and MF, mean HtSDS was −0.6 (−4.8 to 7.8), −0.6 (−2.9 to 2.2), −0.7 (−3.6 to 2.5) and −0.5 (−3.5 to 2.9), respectively. Mean Ht velocity (HV) SDS at T1, T2, T3 and MF was −1.4 (−7.4 to 7.4), −0.6 (−7.5 to 6.1), −0.1 (−6.6 to 7.6) and 0.6 (−4.8 to 7.8), respectively (p<0.05). In final models, HtSDS was associated negatively with the use of prednisolone (p=0.0001), azathioprine (p=0.0001), methotrexate (p=0.0001) and weight SDS (WtSDS) (p=0.0001). HVSDS was associated positively with age (p=0.0001) and WtSDS (p=0.01). ΔHtSDS was associated negatively with use of prednisolone (p<0.02).Conclusion Although current therapy for CD is associated with improved rate of growth for the first few years, a substantial proportion of children remain short. This study also highlights the need for consistency in describing growth in children with chronic diseases.

M3 - Article

VL - 97

SP - 698

EP - 703

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 8

ER -